Experimental Diabetes Research, 2012
With insulin, mild hypoglycaemia signals that dose escalation is progressing faster than the body can handle, prompting a pause or small adjustment
Monzel AS, Enrquez JA, Picard M
The most common adverse events were gastrointestinal disorders, occurring predominantly during dose escalation, with approximately 25% of the participants receiving survotudide and 4% in the placebo group discontinuing treatment, most often because of gastrointestinal disorders [37]
The FDA prescribing information for semaglutide products includes a warning about acute pancreatitis based on postmarketing reports and clinical trial data
If you purchase multiple products, we recommend not incorporating them all at once into your routine